<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Telomerase is the enzyme required for the addition of telomeric repeats to the ends of chromosomes and thus for chromosome stability </plain></SENT>
<SENT sid="1" pm="."><plain>Most somatic human cells lack telomerase activity because they do not express the telomerase reverse transcriptase (hTERT) gene </plain></SENT>
<SENT sid="2" pm="."><plain>In contrast, in almost every <z:hpo ids='HP_0002664'>neoplasia</z:hpo>, <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells express hTERT and therefore prevent progressive telomere shortening during each cell division </plain></SENT>
<SENT sid="3" pm="."><plain>Consecutively, <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells obtain the ability to divide without limits and overcome replicative senescence </plain></SENT>
<SENT sid="4" pm="."><plain>Gene expression level of the telomerase catalytic subunit hTERT in <z:mpath ids='MPATH_458'>normal</z:mpath> and neoplastic haematopoiesis has not yet been described </plain></SENT>
<SENT sid="5" pm="."><plain>Using a quantitative real-time RT-PCR assay, we analysed the level of hTERT expression in various haematologic stem cell disorders and <z:mpath ids='MPATH_458'>normal</z:mpath> bone marrow </plain></SENT>
<SENT sid="6" pm="."><plain>We could demonstrate that hTERT is differentially expressed in various haematologic stem cell disorders with significant higher levels in <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> (RA) and <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>) compared to other haematopoietic stem cell disorders and non-neoplastic haematopoiesis which may be used as a prognostic indicator in these entities </plain></SENT>
</text></document>